Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799240 · ClinicalTrials.gov registry record · Phase 2
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
A Phase 2 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00799240: Completed Phase 2 study, sponsored by University of Kansas.
NCT00799240 is a Phase 2 study that has completed, run by University of Kansas. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00799240, a Phase 2 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor tissue and blood obtained will be done to assess IGF-1R expression and related markers and correlate with response and survival.
Interventions
- DRUG Arm A: Pemetrexed Cisplatin
- DRUG Arm B Pemetrexed, Cisplatin and MK-0646
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT00799240 record still lists
NCT00799240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Arm A: Pemetrexed Cisplatin is the first listed.
NCT00799240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00799240 about?
NCT00799240 is a clinical study titled "MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer". This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor ...
What is the current status of trial NCT00799240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-06. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00799240?
The interventions under investigation include: Arm A: Pemetrexed Cisplatin (DRUG), Arm B Pemetrexed, Cisplatin and MK-0646 (DRUG).
Who is sponsoring clinical trial NCT00799240?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00799240's enrollment target sits among peer trials
27 1697th of 2000 higher than 293 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia